Search for Symbols, analysts, keywords

GMDA Gamida Cell Ltd.
Latest News

$0.860.01 (+1.27%)11:31 AM 09/25/23

NASDAQ | $USD | Realtime

News

Show Full Stories

This feature available only for pro users

Type:

Date Range:

Gamida Cell GAAP EPS of -$0.31 misses by $0.11

Gamida Cell gets new finance chief

Gamida Cell GAAP EPS of -$0.27 in-line

Gamida Cell stock dips after pricing $23M securities offering

Gamida Cell price drops 20% on public offering

Hot Stocks: BLU rises on buy out offer from GSK; ERIC slips on earnings; NVDA, GMDA gains; MP slides

Gamida cell therapy Omisirge for blood cancer patients approved by FDA

Gamida Cell tanks after dismal cash runway guidance for 2023

Gamida Cell GAAP EPS of -$1.24 misses by $0.05

Gamida Cell FY 2022 Earnings Preview

Gamida Cell names Shawn Cline Tomasello chairwoman

Gamida Cell sheds 21% as FDA extends review for lead candidate

Gamida Cell GAAP EPS of -$0.29 beats by $0.02

Gamida Cell Q3 2022 Earnings Preview

Gamida's rises 5% after cell therapy candidate GDA-501 shows promising antitumor activity against HER2+ cancers

Gamida Cell gains on long-term data for blood cancer therapy

Gamida gets $25M debt financing commitment from Highbridge Capital

Gamida Cell shares slide on pricing ~$20M stock offering

Gamida Cell shares slide after stock offering

Gamida appoints Emergent’s former head of vaccines as new CEO

Gamida Cell GAAP EPS of -$0.31 misses by $0.02

Gamida Cell Q2 2022 Earnings Preview

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Gamida Cell completes rolling submission to the FDA for omidubicel

IMMX, ZY and SCOR among premarket gainers

Gamida Cell GAAP EPS of -$0.34 in-line

Gamida Cell stock falls a day after soaring on FDA lifting clinical hold on GDA-201

Gamida stock soars 32% as FDA lifts hold on GDA-201, to start trial for treating blood cancer

Gamida Cell GAAP EPS of -$1.52 misses by $0.10

Gamida Cell surges 22% following rolling BLA submission for omidubicel

Gamida Cell begins rolling submission with FDA for omidubicel for stem cell transplant

Gamida Cell provides key program updates and 2022 outlook

Gamida Cell plans rolling BLA submission for omidubicel for blood cancers; shares up 18%

Gamida Cell EPS beats by $0.14

Gamida Cell EPS misses by $0.36

Gamida Cell EPS beats by $0.06

Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance

Gamida Cell EPS misses by $0.35; outlook

Gamida Cell launches $75M financing with Highbridge Capital Management

Gamida posts positive results from late-stage omidubicel study

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.